Can a cancer drug beat CLL fatigue? small trial hopes to find out

NCT ID NCT02131584

Ongoing Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether ruxolitinib (Jakafi) can reduce fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet ready for standard treatment. Ten participants will take the drug and report their fatigue levels using a simple questionnaire. The goal is to see if the drug improves symptoms like tiredness and swollen lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib (Jakafi)
What this could lead to: If it works, this could offer a way to ease severe fatigue and other symptoms in CLL patients who do not yet need full cancer treatment.
What could go wrong: This is a very small, early-phase study with only 10 participants. It focuses on symptom relief, not curing the disease, and results may not apply to all CLL patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.